[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BG66102B1 - Карбаматни производни на арилалкиламини - Google Patents

Карбаматни производни на арилалкиламини

Info

Publication number
BG66102B1
BG66102B1 BG107474A BG10747403A BG66102B1 BG 66102 B1 BG66102 B1 BG 66102B1 BG 107474 A BG107474 A BG 107474A BG 10747403 A BG10747403 A BG 10747403A BG 66102 B1 BG66102 B1 BG 66102B1
Authority
BG
Bulgaria
Prior art keywords
carbamates
radicals
amine
alkyl
radical
Prior art date
Application number
BG107474A
Other languages
English (en)
Other versions
BG107474A (bg
Inventor
Gallemi Carles Farrerons
RUIZ Juan CATENA
Serrat Anna Fernandez
BONO Ignacio - Jose MIQUEL
Lopez Dolors Balsa
NAVARRO Jose BONILLA
Arnal Carmen Lagunas
Roca Carolina Salcedo
Garcia Andres Fernandez
Original Assignee
Laboratorios S.A.L.V.A.T., S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8494130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG66102(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios S.A.L.V.A.T., S.A. filed Critical Laboratorios S.A.L.V.A.T., S.A.
Publication of BG107474A publication Critical patent/BG107474A/bg
Publication of BG66102B1 publication Critical patent/BG66102B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03B—APPARATUS OR ARRANGEMENTS FOR TAKING PHOTOGRAPHS OR FOR PROJECTING OR VIEWING THEM; APPARATUS OR ARRANGEMENTS EMPLOYING ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ACCESSORIES THEREFOR
    • G03B27/00—Photographic printing apparatus
    • G03B27/02—Exposure apparatus for contact printing
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03B—APPARATUS OR ARRANGEMENTS FOR TAKING PHOTOGRAPHS OR FOR PROJECTING OR VIEWING THEM; APPARATUS OR ARRANGEMENTS EMPLOYING ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ACCESSORIES THEREFOR
    • G03B27/00—Photographic printing apparatus
    • G03B27/02—Exposure apparatus for contact printing
    • G03B27/14—Details
    • G03B27/16—Illumination arrangements, e.g. positioning of lamps, positioning of reflectors
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03B—APPARATUS OR ARRANGEMENTS FOR TAKING PHOTOGRAPHS OR FOR PROJECTING OR VIEWING THEM; APPARATUS OR ARRANGEMENTS EMPLOYING ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ACCESSORIES THEREFOR
    • G03B27/00—Photographic printing apparatus
    • G03B27/02—Exposure apparatus for contact printing
    • G03B27/14—Details
    • G03B27/30—Details adapted to be combined with processing apparatus
    • G03B27/303—Gas processing
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03D—APPARATUS FOR PROCESSING EXPOSED PHOTOGRAPHIC MATERIALS; ACCESSORIES THEREFOR
    • G03D13/00—Processing apparatus or accessories therefor, not covered by groups G11B3/00 - G11B11/00
    • G03D13/002—Heat development apparatus, e.g. Kalvar

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретението се отнася до карбамати, имащи обща структура (I) @където R1, R2 и R3 са Н, OH, SH, CN, F, Cl, Вr, I, (C1-С4)-алкилтио, (C1-С4)-алкоксил, (C1-С4)-алкоксил, заместен с един или няколко F радикали, карбамоиламин, (C1-С4)-алкил и (C1-С4)-алкил, заместен с един или няколко F, или ОН радикали, R4 представлява заместен или незаместен циклоалкилов, или циклоарилов радикал (хетероалкилов радикал, или не). Аминът от хинуклидиновия пръстен може също така да образува кватернерни амониеви соли или да е в оксидирано състояние (N-оксид). Карбаматите (I) са антагонисти на М3 мускариновия рецептор, и селективно, на М2 рецептора. Поради това, те могат да се използват за лечението на незадържане на урина (по-специално дължащо се на нестабилен пикочен мехур), синдром на раздразнителни черва, заболявания на дихателните пътища (по-специално хронично обструктивно пулмонарно заболяване, хроничен бронхит, астма, емфизема и ринити) и при офталмологични операции.
BG107474A 2000-06-27 2003-01-17 Карбаматни производни на арилалкиламини BG66102B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200001661 2000-06-27
PCT/ES2001/000252 WO2002000652A1 (es) 2000-06-27 2001-06-25 Carbamatos derivados de arilalquilaminas

Publications (2)

Publication Number Publication Date
BG107474A BG107474A (bg) 2003-09-30
BG66102B1 true BG66102B1 (bg) 2011-04-29

Family

ID=8494130

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107474A BG66102B1 (bg) 2000-06-27 2003-01-17 Карбаматни производни на арилалкиламини

Country Status (30)

Country Link
US (2) US6916828B2 (bg)
EP (1) EP1300407B2 (bg)
JP (1) JP5046465B2 (bg)
KR (1) KR100751981B1 (bg)
CN (1) CN1227251C (bg)
AP (1) AP1420A (bg)
AT (1) ATE260277T1 (bg)
AU (2) AU2001266100B9 (bg)
BG (1) BG66102B1 (bg)
BR (1) BR0112297A (bg)
CA (1) CA2414514C (bg)
CR (1) CR6889A (bg)
CZ (1) CZ294251B6 (bg)
DE (2) DE60102160T3 (bg)
DK (1) DK1300407T4 (bg)
EA (1) EA005520B1 (bg)
ES (1) ES2213703T5 (bg)
HK (1) HK1054934A1 (bg)
HU (1) HU229306B1 (bg)
IL (1) IL153707A0 (bg)
MX (1) MXPA03000141A (bg)
NO (1) NO328499B1 (bg)
OA (1) OA12300A (bg)
PL (1) PL201530B1 (bg)
PT (1) PT1300407E (bg)
SI (1) SI1300407T2 (bg)
TR (1) TR200400420T4 (bg)
UA (1) UA72632C2 (bg)
WO (1) WO2002000652A1 (bg)
ZA (1) ZA200300644B (bg)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
CA2414514C (en) * 2000-06-27 2009-12-22 Laboratorios S.A.L.V.A.T., S.A. Carbamates derived from arylalkylamines
JP4445704B2 (ja) * 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
ES2266291T3 (es) 2000-12-28 2007-03-01 Almirall Prodesfarma Ag Nuevos derivados de quinuclidina y composiciones medicinales que los contienen.
CA2470567A1 (en) 2001-12-14 2003-06-26 Targacept, Inc. Methods and compositions for treatment of central nervous system disorders
MXPA04006206A (es) * 2001-12-20 2004-12-06 S A L V A T Lab Sa Derivados de 1-alquil-azoniabiciclo(2.2.2(octano carbamato y su uso como antagonistas del receptor musrcarinico.
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
ATE419236T1 (de) 2002-07-08 2009-01-15 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo-3.1.0 hexan- derivate als muscarinische rezeptorantagonisten
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0409302A (pt) 2003-04-11 2006-04-11 Ranbaxy Lab Ltd derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2246170B1 (es) * 2004-07-29 2007-04-01 Almirall Prodesfarma, S.A. Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007007282A2 (en) * 2005-07-11 2007-01-18 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
WO2007024814A1 (en) * 2005-08-22 2007-03-01 Targacept, Inc. HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF
EP1948164A1 (en) 2005-10-19 2008-07-30 Ranbaxy Laboratories, Ltd. Pharmaceutical compositions of muscarinic receptor antagonists
KR20080049113A (ko) 2005-10-21 2008-06-03 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PT2322525E (pt) 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
EP1882691A1 (en) 2006-07-26 2008-01-30 CHIESI FARMACEUTICI S.p.A. Quinuclidine derivatives as M3 antagonists
US20090286779A1 (en) 2006-09-29 2009-11-19 Novartis Ag Pyrazolopyrimidines as lipid kinase inhibitors
PT2104535E (pt) 2007-01-10 2011-03-31 Irm Llc Compostos e composições como inibidores da protease de activação de canal
CA2678193A1 (en) * 2007-02-09 2008-08-14 Astellas Pharma Inc. Aza-bridged-ring compound
EA200901489A1 (ru) 2007-05-07 2010-04-30 Новартис Аг Органические соединения
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
CN104193741B (zh) 2007-10-01 2016-08-24 阿尔法梅根有限责任公司 作为α7-烟碱乙酰胆碱受体配体的奎宁环-4-基甲基1H-吲哚-3-甲酸酯衍生物
EP2065385A1 (en) 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
PE20091096A1 (es) 2007-12-10 2009-08-25 Novartis Ag Compuestos organicos
US8431578B2 (en) 2008-01-11 2013-04-30 Novartis Ag Organic compounds
MX2010008875A (es) * 2008-02-13 2010-08-31 Targacept Inc Agonistas nicotinicos alfa 7 y antipsicoticos.
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
MX2010013675A (es) 2008-06-10 2011-02-15 Novartis Ag Derivados de pirazina como bloqueadores del canal de sodio epitelial.
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
SI2391366T1 (sl) 2009-01-29 2013-01-31 Novartis Ag Substituirani benzimidazoli za zdravljenje astrocitomov
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
US8497368B2 (en) 2009-08-12 2013-07-30 Novartis Ag Heterocyclic hydrazone compounds
ES2709108T3 (es) 2009-08-17 2019-04-15 Intellikine Llc Compuestos heterocíclicos y usos de los mismos
EA201200318A1 (ru) 2009-08-20 2012-09-28 Новартис Аг Гетероциклические оксимы
CN102665715A (zh) 2009-10-22 2012-09-12 沃泰克斯药物股份有限公司 治疗囊性纤维化和其他慢性疾病的组合物
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2011137054A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US9034879B2 (en) 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
EP3964513A1 (en) 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
JP2016512835A (ja) 2013-03-15 2016-05-09 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせ及びそれらの使用
RU2641285C2 (ru) * 2013-07-13 2018-01-17 Бэйцзин Фсвэлкам Текнолоджи Девелопмент Ко., Лтд Соединения хинина, способ их получения и их медицинское применение
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
PT3113772T (pt) 2014-03-07 2020-12-15 Biocryst Pharm Inc Pirazois substituídos por trifluorometilo como inibidores de calicreína plasmática humana
CN106458979B (zh) 2014-04-24 2020-03-27 诺华股份有限公司 作为磷脂酰肌醇3-激酶抑制剂的氨基吡嗪衍生物
MX2016013983A (es) 2014-04-24 2017-04-06 Novartis Ag Derivados de pirazina como inhibidores de fosfatidil-inositol-3-ci nasa.
AU2014391605A1 (en) 2014-04-24 2016-10-27 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
EP3166940A4 (en) 2014-07-11 2018-04-25 Alpharmagen, LLC Quinuclidine compounds for modulating alpha7 -nicotinic acetylcholine receptor activity
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
WO2020250116A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
CN114341132A (zh) 2019-08-28 2022-04-12 诺华股份有限公司 经取代的1,3-苯基杂芳基衍生物及其在治疗疾病中的用途
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
TW202142236A (zh) 2020-02-03 2021-11-16 美商健臻公司 用於治療與溶體儲積症相關的神經症狀之方法
MX2023001014A (es) 2020-07-24 2023-03-01 Genzyme Corp Composiciones farmaceuticas que comprenden venglustat.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006635A1 (fr) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de carbamate et medicament le contenant
EP0747355A1 (en) * 1994-02-10 1996-12-11 Yamanouchi Pharmaceutical Co. Ltd. Novel carbamate derivative and medicinal composition containing the same
EP0801067A1 (en) * 1994-12-28 1997-10-15 Yamanouchi Pharmaceutical Co. Ltd. Novel quinuclidine derivatives and medicinal composition thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3287471A (en) * 1964-05-05 1966-11-22 Searle & Co Pyrrolidinyl nu-phenyl-nu-benzylcarbamates
JPH0495071A (ja) * 1990-08-10 1992-03-27 Kyorin Pharmaceut Co Ltd カルバミン酸誘導体
JPH08198751A (ja) * 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd カルバメート誘導体
CA2414514C (en) * 2000-06-27 2009-12-22 Laboratorios S.A.L.V.A.T., S.A. Carbamates derived from arylalkylamines
JP4445704B2 (ja) * 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
MXPA04006206A (es) * 2001-12-20 2004-12-06 S A L V A T Lab Sa Derivados de 1-alquil-azoniabiciclo(2.2.2(octano carbamato y su uso como antagonistas del receptor musrcarinico.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006635A1 (fr) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de carbamate et medicament le contenant
EP0747355A1 (en) * 1994-02-10 1996-12-11 Yamanouchi Pharmaceutical Co. Ltd. Novel carbamate derivative and medicinal composition containing the same
EP0801067A1 (en) * 1994-12-28 1997-10-15 Yamanouchi Pharmaceutical Co. Ltd. Novel quinuclidine derivatives and medicinal composition thereof

Also Published As

Publication number Publication date
UA72632C2 (uk) 2005-03-15
ES2213703T3 (es) 2004-09-01
TR200400420T4 (tr) 2004-03-22
CN1227251C (zh) 2005-11-16
HK1054934A1 (en) 2003-12-19
PL201530B1 (pl) 2009-04-30
CN1449396A (zh) 2003-10-15
EP1300407B2 (en) 2011-06-08
AU2001266100B2 (en) 2005-06-30
DE60102160T2 (de) 2004-09-09
ATE260277T1 (de) 2004-03-15
HUP0301414A2 (hu) 2003-09-29
DE60102160D1 (de) 2004-04-01
WO2002000652A1 (es) 2002-01-03
JP5046465B2 (ja) 2012-10-10
ZA200300644B (en) 2004-02-10
US7115629B2 (en) 2006-10-03
HU229306B1 (en) 2013-10-28
MXPA03000141A (es) 2003-05-27
AP1420A (en) 2005-05-30
CR6889A (es) 2008-08-21
PT1300407E (pt) 2004-05-31
DK1300407T3 (da) 2004-03-22
KR100751981B1 (ko) 2007-08-28
AP2003002722A0 (en) 2003-06-30
BR0112297A (pt) 2003-05-06
KR20030022159A (ko) 2003-03-15
DE60102160T3 (de) 2012-05-03
EA200300072A1 (ru) 2003-06-26
OA12300A (en) 2006-05-12
NO20026211D0 (no) 2002-12-23
CA2414514A1 (en) 2002-01-03
EP1300407B1 (en) 2004-02-25
US6916828B2 (en) 2005-07-12
AU6610001A (en) 2002-01-08
JP2004501916A (ja) 2004-01-22
DE20122417U1 (de) 2005-08-04
SI1300407T1 (en) 2004-06-30
IL153707A0 (en) 2003-07-06
CZ2003261A3 (cs) 2003-06-18
CA2414514C (en) 2009-12-22
CZ294251B6 (cs) 2004-11-10
NO20026211L (no) 2003-02-26
HUP0301414A3 (en) 2008-03-28
US20040235887A1 (en) 2004-11-25
SI1300407T2 (sl) 2011-09-30
NO328499B1 (no) 2010-03-01
DK1300407T4 (da) 2011-09-05
US20040063950A1 (en) 2004-04-01
EA005520B1 (ru) 2005-04-28
PL359333A1 (en) 2004-08-23
AU2001266100B9 (en) 2005-10-06
ES2213703T5 (es) 2011-11-02
BG107474A (bg) 2003-09-30
EP1300407A1 (en) 2003-04-09

Similar Documents

Publication Publication Date Title
BG66102B1 (bg) Карбаматни производни на арилалкиламини
RS53904A (en) 1-alkyl-1-azoniabicyclo/2.2.2./octane carbamate derivatives and their use as muscarinic receptor antagonists
WO2004074246A3 (en) Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
DE602004021921D1 (de) Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
NO20061454L (no) Compounds having CRTH2 antagonist activity
NO20070387L (no) Kvarternaere salt-CCR2-antagonister
DE60024986D1 (de) Pyrazinyl-piperazin-verbindungen, ihre anwendung und herstellung
WO2000054765A8 (en) Method of treating eating disorders
WO2004054501A3 (en) Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
AU2003281213A1 (en) 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(nk-1) antagonists for the treatment of emesis, depression, anxiety and cough
IL186777A0 (en) (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor
SG154443A1 (en) Piperidine derivatives as nk1 antagonists
WO2003042173A8 (en) Nk1 antagonists
WO2005079496A3 (en) Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
WO2005079497A3 (en) Substituted fused bicyclic amines as modulators of chemokine receptor activity
MXPA05011059A (es) Compuestos de amonio cuaternario y su uso como agentes antimuscarinicos.
WO2005079519A3 (en) Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
CA2246727A1 (en) Novel substituted n-methyl-n-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
MXPA04004075A (es) Compuesto y metodo para tratamiento de vejiga hiperactiva.
NO20063299L (no) Syntese av en polymorf av 4-amino-5-klor-2-metoksy-N-(1-azabisyklo[3.3.1]non-4-yl)benzamidhydrokloridhydrat
WO1998029407A3 (en) N-(pyridinylamino)isoindolines for treating alzheimer's and depression
NO20050147L (no) 1-fenylalkyl-piperaziner
WO2006000324A3 (en) New mao-b inhibitors